Medicus Pharma Ltd. (MDCX) reported on Thursday topline results from its Phase 2 SKNJCT-003 clinical trial evaluating doxorubicin microneedle array or D-MNA, a non-invasive treatment for basal cell carcinoma or BCC. The randomized, placebo-controlled study enrolled 90 patients and assessed two dose levels against placebo.
Results showed increasing clearance rates over time, with the 200-microgram dose achieving 73 percent clinical clearance and 40 percent histological clearance at Day 57.
The company said the data provide decision-grade evidence of clinical activity and may support an end-of-Phase 2 meeting with the U.S. Food and Drug Administration in the first half of 2026 as Medicus explores potential partnerships.
MDCX is currently trading at $0.86, down $0.51 or 36.30 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.